Abstract:
Background and aims: In Bangladesh the brand Weagovy or Mounjaro are not available. So, we are using Biosimilar products .
Materials and methods: Semaglutide and Tirzepatide Open level from local market is used to treat Overweight and obesity with Uncontrolled T2DM. All were Obese or Overweight. Among 30 subjects in each group ( semaglutide Gr: S and Tirzepatide Gr: T) 22 were HTN & Coronary Artery disease and 13 were Diabetic Nephropathy (eGFR less than 60 ml/min). Weigt was identical Mean BMI 26(1.4) and 25(1.2). In S group HbA1c was 9.6(1.5) Vs T group 9.3(1.1).
Results: Mean Duration of DM is more than 7 (2.2) years. Out of 30 subjects in “S” group more than 5 kg weightloss was in 23 % and 10 kg in 11 % in 12 weeks. Out of 30 subjects in “T” group ( Non cohort) 17(56.7%) lost more than 5 kg in 3 months. Five (16.7 %) subjects lost weight more than 10 kg in 12 weeks. 1 patient lost 19 Kg and 2 subject herself stopped the injection, one due to Vomiting and one due to abdominal pain with diarrheas. Patients receiving Tirzepatide 5 mg weekly were significantly more likely to achieve weight loss (≥5%; hazard ratio [HR], 1.72, 95% CI, 1.66, 1.82; ≥10%; HR, 2.50; 95% CI, 2.30, 2.70; and ≥15%; HR, 3.14; 95% CI, 2.71, 3.61). HbA1c reduction was 2.2 % Vs 1.2 % in T group and S group respectively.
Conclusion: Tirzepatide gives dramatic response in reducing blood glucose and weight loss. 5-10 kg. weight loss may be observed in 3months. But there are individual variations. Biosimilar drugs are effective with lower cost. Hba1c reduction is also significantly higher in Tirzepatide group. In both the group Adverse Events( AE) are like originators as per published data.